March 2013
MondayMorning;3/11/2013, Vol. 21 Issue 9, p1
The article presents information on PAR Pharmaceuticals Co. that has agreed to pay 45 million U.S. dollars to settle allegations for improperly labeled and marketed prescription of the drug Megace ES to elderly patients as stated by U.S. Department of Justice. It informs that the company was also accused of criminally misbranding the Megace drug despite being known about its side effects.


Related Articles

  • Settlement speeds Par Pharma's generic launch. Daks, Martin C. // njbiz;5/17/2010, Vol. 23 Issue 20, p2 

    The article reports that Par Pharmaceutical Cos. Inc. will be able to launch its generic cholesterol drug, Zetia, after its partner companies entered into settlement agreement with Merck & Co. Inc.

  • Prohibition against off-label drug promotion challenged. Woodward, Cal // CMAJ: Canadian Medical Association Journal;3/20/2012, Vol. 184 Issue 5, p518 

    The article reports on the lawsuits for prohibiting the off-label drug use wherein Par Pharmaceutical Inc. has gone to court to raise the issue of marketing the megastrol acetate (Megace ES) outside its sanctioned purposes. It explains that it is a crime for manufacturers to advertise drugs for...

  • Teach Patients To Read Their Cold Remedy Labels.  // RN;Jan2003, Vol. 66 Issue 1, p94 

    The article discusses about teaching patients to read labels of over the counter cough and products that contain various combinations of drugs. It is advised that patients should choose drugs selectively by matching ingredients to specific symptoms. Cough/cold drugs may contain...

  • Avastin labelling updated in US to warn of RPLS.  // Reactions Weekly;9/30/2006, Issue 1121, p3 

    The article reports on the changes made to the prescribing information for Avastin in the U.S. to include warning of reversible posterior leukoencephalopathy syndrome (RPLS). Administration of the drug should be stopped in patients developing RPLS, and hypertension treatment should be started....

  • OTIC DISORDERS.  // Monthly Prescribing Reference;Jan2016, Vol. 32 Issue 1, p186 

    The article offers information on several drugs indicated for the treatment of ear infections. The drugs include the Cipro HC Otic and Ciprodex Otic antibiotic and steroid drugs from pharmaceutical company Alcon Inc. and the Cortisporin-TC Otic antibiotic, steroid and surfactant drug from...

  • Par Pharma suit could set up off-label showdown. Arnold, Matthew // Medical Marketing & Media;Nov2011, Vol. 46 Issue 11, p8 

    The article reports on the issue concerning the suit filed by Par Pharmaceutical Cos. Inc. in response to the decision of the U.S. Food & Drug Administration (FDA) regarding the off-label promotion for the approved drug, the Megace ES which is used for managing breast cancer.

  • UnitedHealth Buy to Build on PacifiCare Gets Scrutiny. Reed, Vita // Orange County Business Journal;11/12/2007, Vol. 30 Issue 46, p12 

    The article reports developments in the healthcare industry in California. The acquisition of Sierra Health Services Inc. by UnitedHealth Group Inc. was opposed by American Medical Association. According to researchers at University of California, they have found that neural stem cells may help...

  • Time to make prescribing safety a priority in primary care.  // Reactions Weekly;7/9/2011, Issue 1359, p4 

    The article focuses on a study published in an issue of the "British Medical Journal" which found that high-risk prescribing among patients who are susceptible to adverse drug reactions is common in Scotland.

  • Medicines management. Griffiths, Matt // Nursing Standard;8/13/2008, Vol. 22 Issue 49, p28 

    The article provides an answer to a question on the necessity of reporting the reaction of a patient on the medication and to whom to report.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics